Trial Profile
Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 16 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 26 May 2017 Planned End Date changed from 31 Oct 2018 to 30 Nov 2018.